Update your location to show providers, locations, and services closest to you.
Cancer Specialist (Oncologist), Hematology and Oncology Specialist
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect of biomarkers of XL092 administered alone, and in combination with nivolumab…
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense…
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell…
12 publications
2023
Cancer medicine
PubMed • Publisher's site2022
Future oncology (London, England)
PubMed • Publisher's site2022
Clinical genitourinary cancer
PubMed • Publisher's site2022
Cancers
PubMed • Publisher's site2022
Expert opinion on pharmacotherapy
PubMed • Publisher's site